Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Liquidia Technologies, a privately-held nanotechnology company, has entered into a collaboration and licensing agreement with Abbott to develop Print nanoparticles for the delivery of siRNA-based therapeutics.
Subscribe to our email newsletter
Under the terms of the agreement, Liquidia will provide Abbott with certain rights to Print technology for the development and commercialization of siRNA therapeutics. Financial terms were not disclosed.
According to Liquidia, its Print technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
Neal Fowler, CEO of Liquidia, said: “By combining Abbott’s R&D capabilities with Liquidia’s particle design and delivery expertise, we hope to enable the use of siRNA for therapy and provide more targeted, effective treatment options for cancer patients.”